Magic mushroom compound tested for OCD in small trial
NCT ID NCT06992999
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial will test whether psilocybin, the active ingredient in magic mushrooms, can safely reduce symptoms of obsessive-compulsive disorder (OCD). Twenty adults with moderate-to-severe OCD who haven't responded to standard treatments will receive either a low (10mg) or high (30mg) dose in four supervised sessions over 12 weeks. Researchers will monitor safety, symptom changes, and brain activity using fMRI and EEG.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
psilocybin
What this could lead to
If it works, this could point toward a new treatment option for people with OCD who haven't improved with standard therapies.
What could go wrong
This is a very small, early-phase trial (Phase 1/2) with only 20 people. It primarily tests safety, not effectiveness. High doses may cause intense altered states, and results may not apply to everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBSESSIVE - COMPULSIVE DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Arizona-Tucson
Tucson, Arizona, 85724, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact